1 Parkin DM.Global cancer statistics in the year 2000.Lancet Oncol, 2001,2:533-543.
2 殷正丰. 甲胎蛋白异质体作为肝癌标志物的临床应用.实用肿瘤杂志,2004,19:1-4.
3 沈铮,沈霞.甲胎蛋白及其异质体检测的临床应用价值.上海医学检验杂志,2000,15:361-362.
4 Zoli M,Magalotti D,Bianchi G,et al.Efficacy of a surveillance progra Mfor early detection of hepatocellular carcino ma.Cancer,1996,78:977-983.
5 Golfieri R,Marini E,Bazzocchi A,et al.Small(cm)hepatocellular carcino ma in cirrhosis:the role of double contrast agents in MRimaging vs. Multidetector-row CT.Radiol Med,2009,9:439-466.
6 Sturgeon CM,Lai LC,Duffy MJ.Seru Mtu Mour markers:how to order and interpret them.BMJ,2009,339:b3527-b3535.
7 Maitra A,Thuluvath PJ.GP73 and liver disease:a(Golgi)complex enig ma.AMJGastroenterol,2004,99:1096-1098.
8 Kladney RD,Tollefson AE,Wold WS,et al.Upregulation of the Golgi protein GP73 by adenovirus infection requires the E1 ACtBPinteraction do main. Virology,2002,301:236-246.
9 Block TM,comunale MA,Lo w Man M,et al. Use of targeted glycoproteo mics to identify seru Mglycoproteins that correlate with liver cancer in woodchucks and hu mans.Proc Natl Acad Sci USA,2005,102:779-784.
10 Schwegler EE,Cazares L.Steel LF,et al.SELDI-TOFMSprofiling of seru Mfor detection of the progression of chronic hepatitis Cto hepatocellular carcino ma.Hepatology,2005,41:634-642.
11 Gu Y,Chen W,Zhao Y,et al.Quantitative analysis of elevated seru MGolgi protein-73 expression in patients with liver diseases. Ann Clin Biochem,2009,46:38-43.
12 徐海峰,杨华瑜,张宏冰,等.改变肝癌早期诊断和治疗现状的新肝癌血清标志物.基础医学与临床,2008,28:104-108. |
